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ABSTRACT  
Hepatitis C is the most pressing public health challenge in Egypt where Hepatitis 
C Virus (HCV) prevalence is the highest in the world. In 2015, Egypt Health Issues 
Survey showed that 10% of Egyptians between 15 – 59 years of age had been infected 
with HCV infection, while 7% are chronic active hepatitis C patients. This paper aims 
to estimate the current and future economic and epidemiological burden of HCV 
between 2015 and 2025. In addition, it compares the impact of different scenarios for 
management of this huge public health problem to identify the most cost effective 
strategy capable of reducing the economic and epidemiological burden of this disease 
at the country level. A Markov model representing hepatitis C progression was 
established showing the prognosis among HCV infected cohort within different age 
groups where the members of each group go through predefined states of health over 
one-year time cycles till 2025. The burden of hepatitis C will be estimated through 
calculating different transition probabilities and calculating the direct and indirect 
healthcare cost of the proportion of members who go through each stage of the 
disease and its complications. Under the current management strategy of 125,000 
patients/year, it is estimated that chronic active HCV patients will show minimal 
decrease to reach about 4.1 million cases, with high economic burden of this strategy 
is very high where the direct costs are estimated $23.3 billion, and the total costs are 
$48.3 billion between 2015-2025. While increasing the treatment rate to reach one 
million patient annually for 5 years in addition to decreasing the annual incidence in 
the coming 10 years will drop HCV cases to about 636 thousands by 2025, and with 
only $16.2 billion as a direct costs, and total costs $34.2 billion between 2015-2025 
which is 29.2% lower than the current management scenario.  
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I. Introduction 
 
Hepatitis C is the most pressing public health challenge in Egypt. According to 
World Health Organization (WHO), Egypt has the highest prevalence of hepatitis C 
virus (HCV), where the results of blood screening and testing for the Egyptian blood 
donors showed 20% positive for HCV (GAR-WHO, n.d.). A recently published Egypt 
Health Issues Survey (EHIS) in 2015 on a nationally representative sample showed 
that 10% of Egyptians between 15 – 59 years of age had been infected with HCV 
infection, while 7% are chronic active hepatitis C patients (Ministry of Health and 
Population [Egypt], El-Zanaty and Associates [Egypt], & ICF International, 2015). 
This  warrants the need to investigate the current and the future burden of this disease 
not only from the epidemiological perspective but also from the economic context. 
This knowledge is highly important for evaluating the different scenarios of 
interventions in order to manage this huge public health problem. Having this 
information will make the policy makers in health sectors able to choose the most cost 
effective strategy that is capable of reducing the economic and epidemiological 
burden of this disease at the country level. 
HCV is a RNA virus responsible for the majority of chronic liver disease, 
cirrhosis, and Hepatocellular Carcinoma (HCC) cases in Egypt. HCV is transmitted 
mainly through exposure to infected blood. Historically, the inadequate sterilization 
and reuse of needles in the mass campaigns for treatment of schistosmiasis in Egypt 
between 1960s and 1980s were the main risk factors for this huge prevalence of HCV 
in Egypt (Nafeh et al., 2000; Rao et al., 2002). Recently, about 60% of the cases were 
infected in hospitals and clinics (Yahia, 2011). Also, it was estimated that 24.3% of 
patients were infected through blood transfusion, according to EDHS 2008 (Razavi et 
al., 2014). Also, some social practices, such as sharing common shaving tools at 
barber shops, sharing of home diabetes testing equipment, or toothbrushes are 
considerable risk factors outside the health care settings (Yahia, 2011). 
HCV is the leading cause of chronic hepatitis, liver cirrhosis and hepatocellular 
carcinoma (HCC). About 55%-85% of HCV infected cases become chronic active 
cases and pass through the way of developing fibrosis, cirrhosis, and may progress till 
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become decompensated cirrhosis and HCC (‘WHO | Hepatitis C’, 2015).There are 
many risk factors affecting the rate of progression from one stage to the following one 
in the pathway of the natural history of HCV such as age of the patient, gender, 
alcohol consumption, degree of inflammation and fibrosis of liver biopsy, co-infection 
with HIV or HBV, and other comorbidities (Chen & Morgan, 2006).  
Globally, hepatitis C is a global public health problem where about 130 to 150 
million people suffer from chronic HCV (WHO, 2015). It is estimated that HCV 
related deaths are 350,000 to 500,000 annually. Mapping the prevalence of HCV all 
over the world showed that Africa, Central and East Asia have the highest prevalence 
rate (Hanafiah, 2013). 
In Egypt, the high prevalence of HCV is not the only problem, the high incidence 
of HCV is another important issue which reflects the new HCV infections that occurs 
annually. Literature showed that the incidence ranges from 2 to 6.9/1000 annually 
which means 160,000 to 500,000 new HCV infection occurs annually (Breban et al., 
2013 ; Miller & Abu-Raddad, 2010). This huge number of newly infected cases made 
the problem ongoing and worsen the situation especially with the limited capacities of 
Egyptian Ministry of Health and Population (MOHP) for treating those patients, 
preventing new infections, and the high cost and low efficacy of old treatment 
regimens for HCV. 
Although the problem of HCV in Egypt is huge and ongoing, limited data 
regarding to the economic and in-depth epidemiological burden of disease were 
found. Even with this limitation, the data available regarding the economic burden of 
disease in Egypt became outdated especially after the dramatic changes in the key 
inputs of the previously published models. The main changes were in the baseline 
data of the prevalence of HCV among the different age groups where the previous two 
published models used data from DHS 2008, however, a new DHS report was 
published recently in 2015. Also, new protocols of treatment were approved by 
MOHP which lead to dramatic changes in drug efficacy rather than that used in the 
previously published models, in addition to the most recent dramatic decrease in the 
drugs prices as well. 
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II. Research objectives: 
 
This thesis aims to cover the following areas: 
 Estimate the current and future economic burden of HCV in Egypt 2015-2025: 
This estimation will include the direct burden of HCV represented in the cost 
of HCV treatment regimen, in addition to other medical expenses for 
managing different HCV disease progression stages and complications. Also it 
will estimate the indirect economic burden of the disease such as disability 
adjusted life years (DALYs) to give an estimation for the productivity loss due 
to the disease. Also, the monetary value for DALYs will be calculated. 
 Estimate the current and future epidemiological burden of HCV in Egypt 
2015–2025: 
This part will give an estimation for all HCV viremia cases across the period 
from 2015 to 2015. It also will follow the trend of patients at cirrhosis stage, 
hepatocellular carcinoma, and liver related deaths. 
 Compare the impact of implementing different management scenarios on the 
economic and epidemiological burden of HCV in Egypt 2015 – 2025. These 
three scenarios are: 
o Scenario I: is a mimic for the current situation using the same 
treatment rate, cost of current treatment regimen, efficacy of the used 
drugs, current incidence rate, and estimate the burden of HCV in the 
present and in future if this scenario continue as it is.  
o Scenario II: will study the effect of increasing the treatment rate to 
treat 500,000 cases per year. 
o Scenario III: will discuss the effect of ambitious strategy to treat  1 
million cases in the coming five years and decrease the incidence rate 
by 50% between 2016-2020, then decrease the incidence rate to 
become 10% of the current rate between 2021-2025. 
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III. Literature Review 
 
A. Natural History of the disease: 
1. Causative organism: 
Hepatitis C virus is a RNA virus that replicates in the cytoplasm of liver cells, but 
is not directly cytopathic (Chen & Morgan, 2006). The virus has a high ability for 
replication ranging between 1010  and 1012 virions per day (Neumann et al., 1998). 
There are six genotypes of HCV (Boyer et al., 2002),where HCV genotype 4 is the 
most common one in Egypt which represents more than 90% of the cases (Kamal, 
2007), however, no recent data available about HCV genotype in Egypt as genotyping 
is not routinely done to identify the protocol of management. The virus also has more 
than fifty subtypes (Chen & Morgan, 2006). HCV genome mutate frequently because 
of the weak error proofreading by the viral RNA polymerase in addition to rapid viral 
replication (Bukh, Miller, & Purcell, 1995). Numerous subtypes and frequent 
mutations have made difficulties in discovering vaccine for HCV till now. 
2. Route of transmissions 
HCV is a blood borne virus (i.e. the primary mode of transmission is the 
exposure to infected blood). Risk factors for transmission of HCV include using 
inadequately sterilized medical equipment in health care facilities especially injection 
equipment and poorly sterilized surgical instruments, the transfusion of infected blood 
and blood products (‘WHO | Hepatitis C’, 2015), inadequate commitment to infection 
control measures in hemodialysis units, and injecting drug use through the sharing of 
syringes and needles (Chen & Morgan, 2006). Also, some social practices, such as 
sharing common shaving tools at barber shops , sharing of home diabetes testing 
equipment, or toothbrushes are considerable risk factors outside the health care 
settings (Yahia, 2011). A systematic review analysis for the risk of transmission of 
HCV from infected mother to her baby showed that the rate of infection was 5.8% 
(95% confidence interval [CI], 4.2%–7.8%) for children of HIV-negative women and 
10.8% (95% CI, 7.6%–15.2%) for children of HIV-positive women (Benova et al., 
2014). It is rarely transmitted sexually. This vertical transmission increases in Egypt 
to reach 36% (5/14) according to a study conducted in Alexandria University Hospital 
in Egypt (Kassem, El-Nawawy, Massoud, El-Nazar, & Sobhi, 2000). HCV does not 
spread through casual contact such as sharing food or drinks with an infected person, 
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kissing, and hugging. Also it does not spread through food, water or breast milk 
(‘WHO | Hepatitis C’, 2015). 
3. Disease Progression: 
HCV can cause acute and chronic hepatitis. When person has infection by HCV it 
develop acute hepatitis, however, most of these cases, around 80%, are asymptomatic. 
Only 20% can develop symptoms such as fever, fatigue, nausea, vomiting, decreased 
appetite, abdominal pain, dark urine, grey-colored feces, pain in joints and jaundice. 
Among those who get infection, the HCV virus is spontaneously cleared in 15% to 
45% of cases. Others who do not able to clear HCV by 6 months become chronic 
active cases. HCV begin causing fibrosis in the liver which means excessive 
accumulation of extracellular matrix proteins including collagen (Bataller & Brenner, 
2005). On the long term 15% - 30% of them develop cirrhosis within 20 years. In the 
cirrhotic state, advanced fibrosis occurs and liver loses its normal architecture, 
however it is still able to do many important functions. Cirrhosis may be developed to 
decompensated cirrhosis where the liver becomes unable to do its function well 
leading to variceal hemorrhage, ascites, and hepatic encephalopathy. Also, it could 
develop hepatocellular carcinoma (HCC) (Figure II1). 
Figure ‎III -1  Natural history of infection with hepatitis C virus 
(Chen & Morgan, 2006) 
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There are many variables affect the rate of progression from fibrosis to 
compensated cirrhosis, decompensated cirrhosis, and HCC such as age of the patient, 
gender, alcohol consumption, degree of inflammation and fibrosis on liver biopsy, and 
co-infection with HIV or HBV, and other comorbidities. People who get infected by 
HCV in the forties have higher chances of developing fibrosis than those infected at a 
younger age (Poynard, Bedossa, & Opolon, 1997). It was found that males who have 
daily alcohol consumption 30 g or more are more liable to develop advanced 
progression of liver fibrosis, in comparable to 20g/ day for females (NIH, 2002). 
Also, it was found that presence of HIV with low CD4 count(CD4<200), and HBV as 
well, accelerate the progression of fibrosis in HCV patients (Ragni & Belle, 2001). 
B. Treatment of HCV (old treatment Vs. new treatment) 
1. Obsolete treatment regimen (low efficacy with high side effects): 
Over the past decades, the standard treatment of HCV genotype 4 (HCV- G4) 
patient was a combination of pegylated interferon (PEG-INF) and ribavirin (RBV) for 
48 weeks (Abdel-Razek & Waked, 2015). The efficacy of this combination to treat 
HCV-G4 patient was small. A worldwide study containing 7163 HCV patient treated 
by PEG-IFN/RBV showed only 41% sustained virological response (SVR), defined as 
aviremia 24 weeks after completion of antiviral therapy for chronic hepatitis C virus 
(Marcellin et al., 2012). Also, between 2007 and 2014 the National program for 
control of HCV in Egypt has treated about 350,000 patients  with this combination 
(Doss et al., 2008) and the result showed SVR between 45% and 55% (Esmat et al., 
2014). 
2. Direct acting antivirals (DAAs), the new era for HCV treatment (High 
efficacy with minimal side effects) 
 With discovering DAAs that target specific sites in HCV replication 
complex, a breakthrough in the efficacy of HCV treatment was introduced. There are 
two main classes of DAAs, they differ from each other according to the drug target 
site, and subsequently its efficacy against different genotypes. The first discovered 
DAAs drugs was S3/S4 protease inhibitors, while the second class of DAAs are 
inhibitors of viral polymerase. The first wave of the first generation of protease 
inhibitors is potent against HCV-G1 (Poordad et al., 2011) (Bacon et al., 2011) 
(Sherman et al., 2011) (Jacobson et al., 2011), but not effective against HCV-G4 
(Abdel-Razek & Waked, 2015). That generation included NS3 protease inhibitor and 
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NS4 protease inhibitor (PIs) such as Boceprevir (BOC) and Telaprevir (TVR). Later 
on, the second wave of the first generation of PIs was approved for treatment of HCV-
G4 such as Simeprevir (SIM). The DAAs drugs targeting HCV polymerase includes 
NS5B polymerase inhibitors and NS5A inhibitors. NS5B polymerase inhibitors can 
be divided into two groups: nucleoside inhibitors (NIs) which mimic the natural 
substrates of the polymerase that cause direct chain termination through its 
incorporation into the RNA chain (Asselah & Marcellin, 2012), while the other group 
is non-nucleoside inhibitors (NNIs) which cause conformational protein change 
through binding to one of the sites on HCV polymerase  and inhibit the NS5B (Waked 
et al., 2014). For example, Sofosbuvir (SOF) was approved as NS5B polymerase 
inhibitor drug for treatment HCV-G4, while Daclatasvir (DCV) was approved as 
NS5A polymerase inhibitors for treatment HCV-G4 (Figure III2). 
Figure ‎III -2  New effective drugs against HCV-G4 
 
3. DAA resistance: 
HCV has a high ability for replication ranging between 1010  and 1012 virions per 
day (Neumann et al., 1998). The high error rate of NS%B RNA dependent RNA 
polymerase leads to the possibility of nucleotide substitution in the HCV genome with 
every cycle of replication. This nucleotide substitution may lead to resistance to DAA 
which called resistance associated variant (RAVs) (Abdel-Razek & Waked, 2015).  
On one hand, SOF has a high genetic barrier for resistance. In subjects who 
received SOF in phase III clinical trials, changes in L159F, V321A, and S282T amino 
DAAs 
NS3/NS4 
Protease 
Inhibitors 
e.g. SIM 
Polymerase 
Inhibitors 
NS5B 
Polymerase 
Inhibitors 
e.g. SOF 
NS5A 
Polymerase 
Inhibitors 
e.g. DCV 
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acids were identified. L159F and V321A did not influence the activity of SOF, while 
S282T caused a reduction in susceptibility to SOF in one patient by 13.5 fold (Han, 
Mo, & Wong, 2012).On the other hand, NS%A inhibitors have low barrier for 
resistance. Single mutations at Q30E and Y93N confer high levels of resistance to 
NS5A inhibitors. These mutations were detected in 4.3% of HCV-4 treatment naiive 
patients (McCormick et al., 2014). 
Combining DAAs with different targets of activity limits the effect of these 
mutations and baseline RAVs. For example, patients who experienced failure of PIs 
treatment and had a dominant RAV responded to the combination of SOF/DCV in a 
similar manner as those without baseline RAVs (Sulkowski et al., 2014). 
4. Guidelines for management HCV-G4 using DAAs drugs: 
 
 Guidelines of European Association of Study of Liver diseases (EASL): 
The most recent therapeutic guidelines for HCV-G4 published by EASL was 
released in July, 2015. These guidelines had six treatment options for managing naiive 
and experienced HCV-G4 patients. Two of these options were IFN-containing 
regimen while the other four options were IFN-Free regimen as shown in table III-1 
(‘EASL Recommendations on Treatment of Hepatitis C 2015’, 2015). 
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Table ‎III-1: Summary of EASL recommendations for treatment of HCV-G4 
patients, July, 2015: 
 Regimen Duration 
IFN-containing 
Regimen 
Option 1: 
SOF +  PEG-RBV 
12 wks. 
Option 2: 
SIM + PEG-RBV 
 SIM + PEG-RBV: for 12 wks. 
PEG-RBV: for another 12 wks. in naiive and 
relapse, and for another 36 wks. For prior 
partial and null responders. 
 Stop treatment: if HCV RNA< 25 IU/ml at 
treatment week 4,12 or 24 
IFN-Free 
Regimen 
Option 1: 
SOF + Ledipasvir 
12 wks. 
Option 2: 
Rmbitasvir + 
Paritaprevir + 
Ritonavir   
(± RBV) 
 12 wks. :without cirrhosis 
 24 wks. :with cirrhosis 
Option 3: 
SOF + SIM  
(± RBV) 
12 wks. 
Option 4 
SOF + DCV  
(± RBV) 
 12wks. : naiive patients 
 24 wks.: patient with cirrhosis and 
contraindication for RBV 
(‘EASL Recommendations on Treatment of Hepatitis C 2015’, 2015) 
 Guidelines of American Association for the study of Liver Diseases (AASLD) 
and Infectious Diseases Society of America (IDSA) 
In August 2015, AASLD and IDSA have recommended three treatment 
options for the management of HCV-G4 cases. They recommended option 1 and 2 of 
IFN-Free Regiment in ESAL 2015 guideline, in addition, they also have 
recommended SOF and weight based RBV for 24 wks. They also mentioned two 
alternatives, the first one was SOF plus PEG/RBV for 12 wks. And the second 
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alternative was SOF + SIM (± RBV) for 12 wks. due to limited supportive clinical 
data about this therapeutic option (AASLD/IDSA HCV Guidance Panel, 2015). 
 Egyptian guidelines 
The National Committee for Control of Viral Hepatitis (NCCVH) in May 2015 
has adopted one IFN-based regimen and two IFN- free regimen for treatment of 
HCV-G4 patients in Egypt. The IFN- based regimen was composed of 
SOF+PEG/RBV for 12 wks. For IFN- eligible patient. The second regimen was for 
patient ineligible for interferon where the first option was SOF + SIM for 12 wks., 
while the second option was SOF+RBV for 24wks. For patients who have to take 
amiodarone or cyclosporine drugs (NCCVH, 2015).The inclusion criteria according to 
May 2015 guideline include all HCV RNA positive patients between 18 and 70 years, 
either naiive patients or treatment experienced patients without restriction to their 
fibrosis stage (NCCVH, 2015). 
In November 2015, a new guideline has been published with a significant change 
in the treatment regimen. There were two treatment regimen, where the first regiment 
was for patients who are easy to be treated, and the second one for patients who are 
difficult to be treated. “Easy to Treat” group will get SOF + DCV for 12 wks., while 
the “Difficult to be Treat” group will get SOF + DCV +RBV for 12 wks. (Saeed, 
2015). The inclusion criteria in November 2015 guideline become the same as the 
previous guideline except for the age which increased to include patients from 18 to 
75 years (Saeed, 2015). 
5. Efficacy of oral DAA combinations: 
Using DAAs for treatment HCV-G4 has showed significant increase in cure rate 
where SVR has reached nineties in some combinations. For example, in Doss et al. 
2015, using SOF + RBV among Egyptian patients with G4 for 24 wks. showed 92% 
and 89% SVR among naïve and experienced patients respectively; and SVR among 
cirrhotic and non-cirrhotic were and 78% and 93% respectively, with an average SVR 
90% ( Doss et al., 2015). In another paper studied the efficacy of triple therapy, SOF+ 
PEG/RBV for 12 wks., on HCV-G4 showed that SVR was 80% among cirrhotic 
while it was 84% among non-cirrhotic, and the total SVR was 83.3% (Wehmeyer et 
al., 2015. 
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6. Cost of the obsolete regimen versus DAAs regimens: 
 The last price for the treatment course of PEG-INF/RBV for 48 wks. in Egypt 
was about $ 2000. On the other hand, the price of the new DAAs drugs was very 
expensive in US and Europe. For example, the initial price of SOF was $84,000 for 
12-wk course, and the price of SIM was $ 60,000 for 12-wk course (Fick & Hirschler, 
2014), while the Egyptian government succeeded in its negotiation with Gilead 
Science to get SOF for 12 weeks at $900 only (Wanis, 2014) (Fick & Hirschler, 
2014), and this price became the standard for the India and other developing countries 
(Palmer, 2014). Hence, the cost of the triple therapy (SOF+PEG-IFN/RBV) became $ 
1500 (Abdel-Razek & Waked, 2015). Recently, head of NCCVH declared that the 
cost of the whole course of SOF+DCV that has been approved for treatment of HCV 
patient in the last treatment protocol in December 2015 will be only $ 319.3 (2500 
LE) (Abdelsalam, 2015).  
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C. Epidemiological Burden 
 
1. Global Burden 
Hepatitis C is a huge public health problem facing many countries in the world 
(Mathurin, 2013). It is estimated that 130 to 150 million people globally suffer from 
chronic hepatitis C (WHO, 2015) which comprises about 3% of the world population 
(NIH, 2002). A significant number of those patient will develop complications such as 
liver cirrhosis and liver cell failure and hepatocellular carcinoma. WHO estimated that 
350,000 to 500,000 people die each year from hepatitis C-related liver diseases 
(WHO, 2015). 
Figure ‎III -3  Distribution of HCV all over the world 
(Hanafiah, 2013) 
Figure III3 shows the prevalence of HCV globally where Africa and Asia (Central 
and East) have reported the highest prevalence rates, while North America, Western 
Europe, and Australia reported low rates of HCV. 
Globally, HCV genotype 1 (HCV-G1) is the most common genotype which 
represents about 46% , followed by HCV-G4  with 22%, HCV-G2 with 13%, and G4 
with 13%. There is variation in dominance of HCV genotypes across the continents 
where HCV-G1is dominant in Europe, North America, south America, and Australia 
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which represent  53-71% of all cases; however, G3 is the dominant genotype in Asia 
(40%), on the other hand, in North Africa and Middle East G4 is dominant (71%), 
however, if Egypt was excluded, G1 will be the dominant (46%) as G1 will decrease 
to 34% of all infections in the region (Gower et al., 2014). 
2. Burden in Egypt 
2.1 Incidence of Hepatitis C 
Four studies calculating the incidence of hepatitis C in Egypt by prospectively 
assessing cohort of Egyptian regarding positivity and negativity to HCV antibodies, 
then follow up the negative people to identify incident cases were reviewed. The first 
two studies estimated the incidence among population of rural villages. 6,734 
Egyptians living in two rural village in lower and upper Egypt were assessed and 
followed up to calculate the incidence of HCV (Mohamed et al., 2005). The incidence 
among village resident in Qalubyia, Lower Egypt was 6.8/1,000 person- years, while 
the incidence among village residents in Assuit, Upper Egypt governorate was 
0.8/1,000 person-years (Mohamed et al., 2005). Another 4 years cohort study were 
conducted in Menoufia governorate, Lower Egypt where the incidence was 2.4/1000 
PY (95% CI: 1.6–3.5) (Mostafa et al., 2010). The second two studies calculated the 
incidence in specific groups such as children and pregnant women. 2852 uninfected 
infants from three villages with high HCV prevalence were prospectively followed 
from birth for up to 5.5 years where the incidence rate was 2.7/1000 PY (Doa’a et al., 
2008). And for about 2.2 years, 2171 pregnant women in three rural Egyptian village 
were followed up to calculate the incidence of HCV among pregnant women. The 
results showed that the estimated HCV incidence was 5.2/1000 PY (Doa’a et al., 
2008). 
Another two studies built mathematical model to estimate the incidence of HCV 
in Egypt. In 2010, Miller et al build their model using age-specific prevalence 
extracted from a population based survey, EDHS 2008. The estimated incidence was 
6.9/1,000 (95% CI, 5.5–7.4) PY which means that more than 500,000 new HCV case 
per year were infected (Miller & Abu-Raddad, 2010). On the other hand, in 2013, 
another model was conducted to address the assumption of time-independent 
epidemiology to reach more realistic estimate. This model estimated the incidence of 
HCV nationwide at around 2.0/1000 PY which means around 150,000 new infections 
annually (Breban et al., 2013). The difference between the two models may be due to 
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spatial heterogeneity of HCV prevalence and also present different incidence 
estimates for young adults. 
2.2 Prevalence of hepatitis C 
Prevalence in general population 
Several studies investigated the prevalence of HCV among general population in 
Egypt. In 2008, Egypt Demographic and Health Survey (EDHS) using a national 
representative sample estimated the prevalence of HCV to be 14.7% among Egyptian 
aged 15-59 years old using HCV antibody test which means that those people had 
been exposed to HCV, while the cases with active infection with viremia were 9.8 % 
using HCV RNA PCR test (El-Zanaty & Way, 2009). Recently in 2015, the newly 
published Egypt Health Issues Survey (EHIS) showed that the prevalence of anti 
HCV and HCV RNA among the same age group was 10% and 7%; respectively. By 
adding a new age group from 1-14 years to the previous estimate, the prevalence of 
anti-HCV and HCV RNA among age group from 1- 59 became 6.3% and 4.4%; 
respectively due to low prevalence of HCV among young age people (Ministry of 
Health and Population [Egypt], El-Zanaty and Associates [Egypt], & ICF 
International, 2015).  
According to EHIS 2015, the prevalence of HCV among males are more than 
females, and there was a marked difference between age 50-54 and 55-59. For 
example, the prevalence of HCV viremia among male and female in age group 55 to 
59 was 27.8% and 17.8% respectively. Also, the prevalence of active hepatitis showed 
a positive relationship with age where the prevalence among older age groups is much 
higher than the younger ones. For example, prevalence of active hepatitis in age 
groups below 20 was less than 1% while it reached 22.1% among age group 55-59 
years as presented in figure III4. 
It was found that the social determinants of health (SDH) such as place of 
residence, socioeconomic level and level of education have significant impact on the 
prevalence of HCV. According to EHIS 2015, the prevalence of active hepatitis cases 
in rural areas was higher than urban areas where it is 5.1% and 3.1%; respectively. In 
addition, the prevalence in Lower Egypt governorates is the highest (5.6%), while 
urban governorates showed the lowest prevalence (3%). Also, it was clear from the 
results that the prevalence of active hepatitis C cases increase with lower wealth 
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quintile groups and decrease with the increase of wealth quintile level. For example, 
HCV-RNA prevalence among lowest wealth quintile was 5.8%, while it was only 
2.6% among the highest wealth quintile (Ministry of Health and Population [Egypt], 
El-Zanaty and Associates [Egypt], & ICF International, 2015). Regarding to the 
relation between educational level and HCV prevalence, it was found that it is higher 
in illiterate people (14.5%) while it was much lower among people who have 
completed secondary education and higher (4.1%) (El-Zanaty & Way, 2009). 
 
Figure ‎III -4   Prevalence of active hepatitis by age, Egypt 2015 
 
 
Prevalence among high-risk groups 
There are different high risk group for HCV where the prevalence increases 
among them. These groups include schistosomiasis patients, patients on hemodialysis  
multi-transfused patients, thalassemia patients, IDUs, healthcare workers and barbers. 
Treatment of schistosomiasis patients by using parenteral anti-schistosomal therapy 
(PAT) campaigns is believed to be the major historic cause for increase the 
prevalence of HCV in Egypt (Frank et al., 2000). MOH treated millions of Egyptians 
using intravenous tater emetic drugs in between 1950s and 1980s (Strickland, 2006). 
During these large scale campaigns, reuse of glass syringe and improper sterilization 
measures have caused the HCV epidemic in Egypt (Yahia, 2011). Multiple studies 
were conducted to identify the prevalence of HCV among multi-transfused children 
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where the average prevalence was 58%. And the average among children with 
thalassemia was 58% (Mohamoud et al., 2013). High HCV prevalence rates were 
observed with averages of about 42% among multi-transfused children and about 58% 
among children with thalassemia. Multiple studies were also conducted among 
hemodialysis patients (mostly adults). Very high HCV prevalence was found in both 
adult populations and children on hemodialysis. Regarding the prevalence among 
hemodialysis patient, 94.1% of them had HCV according to a study conducted in 
Mansoura Dakahlia, Lower Egypt (Kassem et al., 2000) , while the prevalence 
decreased to 70% in Cairo (Ibrahim, 2010). The burden of disease among healthcare 
workers is also high where HCV prevalence was about 17% in average (Mohamoud et 
al., 2013). Also it was found that the prevalence among barbers reached 12.3% 
(Shalaby et al., 2010). 
2.3 Evidence of ongoing transmission 
Although Egypt has the highest HCV prevalence in the world, but the most 
serious problem is the ongoing transmission of this virus till now. As the capacity of 
treatment is less than the incidence rate of HCV.  In 2013, Mohamoud et al. 
conducted build multiple regression model to follow the trend of HCV prevalence 
over time. They built multiple regression analysis which showed no significant 
decrease in the prevalence of HCV over time (P-value: 0.215) (Mohamoud et al., 
2013). Recent studies suggest the iatrogenic (healthcare) exposures is the underlying 
cause for ongoing transmission of the disease in Egypt (Miller & Abu-Raddad, 2010) 
(Talaat et al., 2006). 
2.4 Published model for estimating the epidemiological burden: 
In 2014, Razafi et al. developed a mathematical model to estimate the present and 
future burden of hepatitis C virus. It was the first trial to give in-depth insight about 
the epidemiological burden of the hepatitis C in Egypt. A disease progression model 
was developed using Microsoft Excel where the model start with new acute hepatitis 
C cases that develop chronicity in addition to chronic viremic HCV case. These cases 
go through the model and progress from on stage to another according to certain 
probabilities as in Figure III5. It moves between different stages of fibrosis (F0, F1, 
F2, and F3) till reach cirrhotic stage, then it develop decompensated cirrhosis which 
has different forms such as variceal hemorrhage, hepatic encephalopathy, and ascites. 
It may develop also hepatocellular carcinoma. The chronic HCV cases may end up 
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with cure after getting suitable treatment, liver transplantation, or death due to liver 
related mortality (Razavi et al., 2014).   
Figure ‎III -5  The flow of HCV disease progression model of Razavi et al., 2014 
 
 (Razavi et al., 2014) 
NC= New Cases , TC= Total Cases 
This study showed the burden of the disease in 2013 and the estimated future 
burden by 2030 as shown in table III-2.  
Table ‎III-2 Estimate of HCV disease burden in 2013 and 2030, in Egypt: 
 2013 Estimate 2030 Estimate % change 
Viremic HCV infection 5,980,000 4,420,000 ( 20) 
HCC Cases 16,100 18,300 15 
Liver Related Mortality 33,000 36,500 10 
Decompensated Cirrhosis 137,000 136,000 (1) 
Compensated Cirrhosis 626,000 611,000 (2) 
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(Razavi et al., 2014) 
One of the main limitations for this model is that it did not take into 
consideration the progression of disease in cured cases or spontaneously cured cases 
which may got the infection again with HCV. Also it may progress to advanced stages 
and develop liver related complications in slower rate despite of viral clearance. This 
issue may lead to underestimation for cases of decompensated cirrhosis and 
hepatocellular carcinoma as well. Another important issue is that there are many 
variables used in this model which have been dramatically changed in the last two 
years. First, the drugs available at the time of developing this model for treatment 
HCV were pegylated interferon (Peg-INF) and ribavirin (RBV) which have many side 
effect and contra indications for this treatment, therefor, only 40%  to 60% of HCV 
patient were eligible for getting Peg-INF/ RBV (Morrill, Shrestha, & Grant, 2005). 
Second, the Sustained Viral Response (SVR 24) which defined as aviremia 24 weeks 
after completion of antiviral therapy for chronic HCV infection (Pearlman & Traub, 
2011), this SVR for Peg-INF/ RBV was 48% (Razavi et al., 2014), which means that 
only 48% of people who received this regimen were cured. However, nowadays after 
discovering Sofosbuvir (SOF) the SVR 12 for the triple therapy containing SOF, Peg-
INF/ RBV for 12 weeks is 83.3% (Wehmeyer et al., 2015) and  90% for dual therapy 
containing SOF and RBV for 24 weeks (Doss et al., 2015) with average 86.65%. 
Third, the number of annually treated patient in Egypt used in this model was 65,000 
patient per year where 77% of them got their treatment in the liver treatment centers 
affiliated to Ministry of Health and Population (Doss et al., 2008),15% of them got 
their treatment from Health Insurance Organization (HIO), and 8% of them got their 
treatment as out of pocket. However, recently the number of people receiving the 
treatment annually has increased to 125,000 patients per year (Donald, 2015).  
Two recent studies addressed estimation for the current and the future burden 
of HCV in Egypt when applying different scenarios regarding to treatment rate and 
treatment efficacy. In 2014, Waked et al used the previously illustrated mathematical 
model developed by Razavi et al (Razavi et al., 2014). This paper studied three 
scenarios where the basic one assume fixed number for annually treated patient, 
eligible patient for treatment, the number of newly diagnosed patient between, and 
efficacy of the drugs, 2013 till 2030 (Waked et al., 2014). The second scenario 
assumed increasing efficacy of the drugs to become 90% rather than 48% in the first 
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scenario, and increasing the percentage of people eligible for getting the treatment to 
reach 90% compared to 50%, while the third scenario assumed increasing the drug 
efficacy and treatment eligibility such as previous scenario, in addition to increasing 
the treatment rate to reach 325,000 patient by 2018 rather than 65,000 in the second 
scenario (Waked et al., 2014). The impact of each scenario are shown in table III-3 
Table ‎III-3 The impact of different treatment scenarios on the morbidity and 
mortality of HCV, in Egypt: 
 2013 
Estimate 
2030 Estimate 
Scenario 
(1) 
Scenario 
(2) 
Scenario 
(3) 
No. of total infected 
% of change from 2013 
6,000,000 
 
4,420,000 
-26% 
4,045,000 
-32% 
280,000 
-95% 
No. of compensated cirrhosis 
% of change from 2013 
630,000 610,000 
-2% 
507,000 
-19% 
76,000 
-88% 
No. of decompensated cirrhosis 
% of change from 2013 
138,000 136,300 
-0.6% 
110,000 
-21% 
17,000 
-87% 
No. of HCC 
% of change from 2013 
16,000 18,500 
+15% 
16,000 
0% 
2,400 
-85% 
No. of HCV related Mortality 
% of change from 2013 
33,000 36,500 
+10% 
30,700 
-7% 
7,500 
-77% 
(Waked et al., 2014) 
Regarding to the design of this model, our previously mentioned criticism is 
still valid as Waked et al., 2014 used the model of Razavi et al., 2014 as is. Although 
the authors updated some of data used in the model, these data become now outdated. 
For example, they added the SVR of the new DAA drugs that have reached phase II 
and phase III clinical trials and are expected to be in the market soon. They expected 
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SVR for this new drugs at that time to be 90%, however the recent studies showed 
that the SVR for these drugs after using it on large scale to range from 83.3% for 
triple therapy (Wehmeyer et al., 2015) to 90% for dual therapy (Doss et al., 2015) 
with average 86.65%. Another issue, the inclusion criteria used in this paper for the 
persons eligible for treatment were age form 15-59 years old, and the histological 
state of liver fibrosis was more or equal to F2, however the current inclusion criteria 
published in May 2015 included wider age group from 18-70 years old, and also 
include all fibrotic stages including F0 and F1 which will lead to changes in the 
outcomes of the model (NCCVH, 2015). 
The second study addressed the estimation of the current and the future burden 
of HCV in Egypt when applying different scenarios regarding to treatment rate and 
treatment efficacy was conducted by Shelbaya et al., 2015. They developed Markov 
model to model the transition of HCV infected cohort among different age groups 
using Egyptian DHS 2008 through following them up over time. In this Markov 
model, members of the cohort go through predefined states of health over a period of 
time where the patients move between different health states of the liver disease such 
as F0, F1, F2, F3, compensated cirrhosis, and complication and liver related death 
according to specific probabilities. Then the burden of HCV (morbidity and mortality) 
was estimated for the cohort. 
The results of the model showed that the current treatment rate for about 
65,000 patient/ year will lead to increase the annual number of HCV related deaths in 
Egypt from  about 15,000 deaths/year in 2015 to about 40,000 deaths/year by 2030 
(Shelbaya et al., 2015). Also, all cirrhotic cases is expected to increase from 750,000 
cases in 2015 to reach the peak by 2022 where it will be 925,000 cases then slightly 
decrease to reach 800,000 cases by 2030 (Shelbaya et al., 2015). The paper showed 
that with the increase the rate of treatment to 8% i.e. treating 300,000 - 450,000 
patients the expected total viremic HCV cases will reach 1,000,000 cases by 2030, 
number of liver related deaths will be lower than 15,000 deaths, and the number of 
patients with cirrhosis will decline by 87 % to reach about 100,000 cases by 2030 
(Shelbaya et al., 2015). 
Although this model tried to mimic the natural history of the disease and the 
possible progression events that could happen, however, there are some issues 
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regarding the design of the model. First, according to the model, the patient who got 
the treatment and not cured they either stay in the same health state or progress to the 
next one, where it is possible to get the treatment another time which may lead to 
overestimate for the economic burden of the disease. Second, one of transition states 
in the model for health states F0, F1, F2, F3, F4, compensated cirrhosis, and 
decompensated cirrhosis health states was “New Incidence” transition state which 
represents the probability of developing new incident case from the previous health 
state. However, this probability to develop new incident case should be allocated only 
to susceptible individuals who are HCV free or cured and should not be allocated to 
individuals with the disease. 
D. Economic burden 
Limited literature were found covering the aspect economic burden of HCV in 
Egypt. The two previously reviewed models in this paper of Razavi et al. 2013 and 
Shelbaya et al. 2015 were used to estimate the current and future economic burden of 
HCV in Egypt. 
In Estes et al., 2015 model, the direct health care cost  and indirect burden of 
HCV in Egypt was calculated between 2013 and 2030 through using the model 
established by Razavi et al. 2013 , where direct health care cost was calculated based 
on data collected from the National Liver Institute which is a representative of 
governmental hospitals. Also, indirect costs were estimated based on calculating 
disability adjusted life years (DALYs) which includes years of life lost to disability 
(YLD) and years of life lost due to premature death (YLL); in addition the value of 
lost productivity was estimated using Egyptian estimates for the value of a statistical 
life year (VSLY). The same previously used scenarios in Waked et al., 2014 to 
estimate the economic burden were used by Estes et al., 2015 to calculate the 
economic burden as well, where the first scenario had the old treatment with 48% 
SVR and treated cases annually is about 65,000; the second scenario with 90% SVR 
and 65,000 treated cases annually; while the third scenario had 90% SVR and 325,000 
treated cases annually. 
The results of the model presented in Table III-4 showed that the old regimen 
of treatment and number of annually treated burden will result in $ 89.1 billion as a 
cumulative total cost for HCV, however the new introduced HCV drugs with high 
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SVR will decrease the burden by 3.7%, while increasing the rate of treatment using 
this drugs as in scenario no. 3 will cause significant decrease in the burden of HCV by 
35.4% to reach $57.6 billion (Estes et al., 2015). 
Table ‎III-4 Direct and indirect costs by Scenario – Egypt, 2015–2030 
 Scenario (1) Scenario (2) Scenario (3) 
Cumulative disability adjusted 
life years 2013–2030 
% of change from scenario (1) 
7,875,440 7,343,640 
 
-6.8% 
4,923,210 
 
-37.5% 
Cumulative direct costs 
2013–2030 (US $) 
% of change from scenario (1) 
23,244,377,860 24,192,586,440 
 
4.1% 
18,632,607,710 
 
-19.8% 
Cumulative indirect costs 
2013–2030 (US $) 
% of change from scenario (1) 
65,822,552,110 61,547,348,360 
 
-6.5% 
38,929,874,750 
 
-40.9% 
Cumulative total costs 2013–2030 
(US $) 
% of change from scenario (1) 
89,066,929,970 
 
85,739,934,800 
 
-3.7% 
57,562,482,460 
 
-35.4% 
(Estes et al., 2015) 
Shelbaya et al., 2015 model showed that the estimated cost of applying policy 
of 1% treatment rate will be $600 million in 2015 then decline to $500 million by 
2030 where all viremic HCV cases will decline by 15% to reach about 5.5 million 
cases, while with 5% treatment rate it decline from at $900 million in 2015 to $550 
million by 2030 where this policy will lead to decrease the all viremia cases by 61% 
to reach 2.5 million cases (Shelbaya et al., 2015). However, the cost of treatment of 
the suggested policy by the paper, 8% treatment rate, was $ 1.3 billion in the first year 
of treatment then decrease gradually to reach $ of $580million by 2030, where all 
viremia cases will decrease by 84.6% to reach 1 million cases by 2030 (Shelbaya et 
al., 2015). 
On one hand, in Shelbaya et al. 2015, the cost of the treatment was updated to 
match the new prices of the new drugs available for treatment HCV. On the other 
hand, all the estimates of the cost data were based on expert opinion from a Delphi 
panel of local experts. Also, it is not clear if this is the cost of triple regimen or the 
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dual regimen as the available published model is just poster presentation, therefore 
did not contains much detailed information. Another comment regarding to the cost 
estimate is that the cost estimate for liver transplant in first year is very small ($ 
1.197), as the cost of liver transplant surgery is much higher than this cost. According 
to Khalaf et al., 2005 the cost of living donor liver transplantation (LDLT) in a private 
based hospital is about $ 70,000 while it reaches $ 25,000 in governmental hospital, 
also a recent estimate in 2015 showed that the cost is about $ 42,000 according to data 
collected from the National Liver Institute (NLI), a nationally representative 
government hospital (Estes et al., 2015). This very low cost estimate for liver 
transplant may lead to underestimation of the real burden of the diseases. 
E. Other types of disease burden: 
Lack of awareness about Hepatitis C in the community often leads to 
misinformation, missing of opportunities for prevention and treatment, and 
stigmatization of infected populations. level of support that someone with chronic 
hepatitis C might receive was less when compared to someone with a chronic illness 
that does not carry a stigma which might affect self-esteem and cause decrease in the 
quality of life (Ibrahim & Madian, 2011). This stigma of the disease push 30.9% of 
the patients to conceal the nature of their illness and 24.4% of them even conceal this 
information from their families, according to a study conducted in Elghar village, 
Zagazig governorate (Eassa et al., 2007). Also, HCV patients are not allowed to travel 
to gulf countries for work. This opportunity lost due to inability of traveling for 
working in certain countries are not included in our analysis in the thesis. 
F. National Strategy for Prevention and Control 2014-2018 
As Egypt is the highest country in the world in the prevalence of HCV, World 
Health Organization (WHO) has called experts from head quarter in Geneva, Center 
of Disease Control and Prevention (CDC) in U.S, NAMRU-3, and Institut 
Pasteur/Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) 
to support Egypt in building a comprehensive national strategy for prevention and 
control of HCV. Multiple mission in different specialties visited Egypt to conduct gap 
analysis, then began in cooperation with MOH official and Egyptian NGOs to 
establish “Plan of Action for the Prevention, Care and Treatment of Viral Hepatitis, 
Egypt, 2014-2018” (MOHP, 2014).  
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The plan of action is composed of seven pillars to ensure efficient prevention 
and control of viral hepatitis. The first pillar aimed to strengthen national surveillance 
system for viral hepatitis to follow the trend of the disease, identify risk factors, and 
measure the impact of implementation of the prevention and control program. The 
second pillar is focused on infection control where it aimed to decrease transmission 
of viral hepatitis through health care facilities, promote safe injection, and strengthen 
monitoring and evaluation program to ensure proper implementation for infection 
control measures. The third pillar focused on blood safety through different activities 
such as establishing national standards for blood transfusion and management, 
enhance the capacities of blood banks in blood screening and testing, capacity 
building for staff working in blood banks, and developing IT component to increase 
safety of collected blood and enhance blood management system. The fourth pillar is 
focused on vaccination against Hepatitis B where it aimed to achieve universal 
vaccination among high risk groups, and ensure implementation of zero dose of 
against HBV for all newborn in the first 24 hours after birth. The fifth pillar is 
concerned with raising awareness regarding to mode of transmission and methods of 
prevention among community. The sixth pillar is dedicated to ensuring availability 
and accessibility of effective drugs for treatment of viral hepatitis. The seventh pillar 
is concerned with scientific research to fill the gap in knowledge in hepatitis issues, 
and translate this knowledge into policies and practices (MOHP, 2014). 
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IV. Methodology: 
A. Model Description 
A model representing hepatitis C progression was established by using 
Markov model showing the prognosis among HCV infected cohort within different 
age groups using Egyptian DHS 2015 results, then following each age group cohort 
between 2015-2025. In this Markov model, the members of each age group go 
through predefined states of health over one-year time cycles till the end of the 
predefined period of time to 2025. The current and future epidemiological burden 
(morbidity and mortality) and economic burden as well of hepatitis C will be 
estimated through calculating different transition probabilities and calculating the 
direct and indirect healthcare cost of the proportion of members who go through each 
stage of the disease and its complication.  
First, all Egyptian population between 1-59 years will be divided according to 
their age into 5 years interval age groups. Then, each cohort will move through the 
same health states with different probabilities according to the age. The health states 
were based on presence or absence of hepatitis C viremia, liver histology, 
decompensated liver disease, hepatocellular carcinoma, or liver transplantation. The 
hepatic patient has three histological states based on Metavir classification, F0, F1, F3 
and cirrhotic stage. Over a period of time the patient go from a stage to the following 
or stay at his stage. For example, patient in F0 state after one year could become in F1 
stage or stay at F0 stage and so on. The data required for this model such as 
probability of transmission from stage to another, cost of health care services and 
utilities of different health states will be gotten from literature and will described in 
details in “Model Input” section. Annex 1 contains the model structure. 
The health states included in the models are: 
 HCV free population: This group includes all the people in this age group who 
are not suffering from Viremic HCV, while the following health states 
includes patients who has HCV viremia 
 F0_treatment: This group includes the people in this age group who have 
viremia and their histology according to Metavir criteria showed that they 
have no fibrosis (F0 stage) (Goodman, 2007). Also, the patient in this age 
group may get or not get the treatment according to many scenarios such as 
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probability of diagnosis and availability of drug and eligibility for going 
through the treatment protocols 
 F0_ treatment failure: This group includes the people in this age group who 
have viremia and their histology according to Metavir criteria showed that 
they have no fibrosis (F0 stage) , and they got HCV treatment previously; 
however, they did not show SVR (i.e. treatment failure) 
 F1_ treatment: This group includes the people in this age group who have 
viremia and their histology according to Metavir criteria showed that they 
have portal fibrosis without septa (F1 stage) (Goodman, 2007). Also, the 
patient in this age group may get or not get the treatment according to many 
scenarios such as probability of diagnosis and availability of drug and 
eligibility for going through the treatment protocols 
 F1_ treatment failure: This group includes the people in this age group who 
have viremia and their histology according to Metavir criteria showed that 
they have portal fibrosis without septa (F1 stage), and they got HCV treatment 
previously; however, they did not show SVR (i.e. treatment failure) 
 F2_ treatment: this group includes the people in this age group who have 
viremia and their histology according to Metavir criteria showed that they 
have  portal fibrosis with few septa (F2 stage) (Goodman, 2007). Also, the 
patient in this age group may get or not get the treatment according to many 
scenarios such as probability of diagnosis and availability of drug and 
eligibility for going through the treatment protocols 
 F2_ treatment failure: This group includes the people in this age group who 
have viremia and their histology according to Metavir criteria showed that 
they have portal fibrosis with few septa (F2 stage), and they got HCV 
treatment previously ; however, they did not show SVR (i.e. treatment failure) 
 F3_ treatment: This group includes the people in this age group who have 
viremia and their histology according to Metavir criteria showed that they 
have  portal fibrosis with numerous septa without cirrhosis (F3 stage) 
(Goodman, 2007). Also, the patient in this age group may get or not get the 
treatment according to many scenarios such as probability of diagnosis and 
availability of drug and eligibility for going through the treatment protocols. 
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 F3_ treatment failure: This group includes the people in this age group who 
have viremia and their histology according to Metavir criteria showed that 
they have portal fibrosis with numerous septa without cirrhosis (F3 stage), and 
they got HCV treatment previously; however, they did not show SVR (i.e. 
treatment failure) 
 Compensated Cirrhosis: This group includes the people in this age group who 
have viremia and the liver has irreversible diffuse disorganization of its 
normal structure (El Saadany et al., 2005); however, it is still able to perform 
many important functions (Franciscus, 2015). Also, the patient in this age 
group may get or not get the treatment according to many scenarios such as 
probability of diagnosis and availability of drug and eligibility for going 
through the treatment protocols 
 Compensated Cirrhosis with treatment failure: This group includes the people 
in this age group who have viremia and the liver has irreversible diffuse 
disorganization of its normal structure (El Saadany et al., 2005)  ; however, it 
is still able to perform many important functions (Franciscus, 2015) Also, the 
patient in this age group may get or not get the treatment according to many 
scenarios such as probability of diagnosis and availability of drug and 
eligibility for going through the treatment protocols. The patients in this group 
got HCV treatment previously ; however, they did not show SVR (i.e. 
treatment failure) 
 Diuretic Sensitivity Ascites: This group includes the people in this age group 
who have viremia and decompensated cirrhosis where the liver is extensively 
scarred and unable to do its function well (Franciscus, 2015), which leads to  a 
measurable accumulation of intra-abdominal fluid due to the increase in portal 
venous pressure(El Saadany et al., 2005),and this ascites can be treated with 
dietary sodium restriction and oral diuretic (Arroyo et al., 1996) 
 Diuretic Refractory ascites: This group includes the people in this age group 
who have viremia and decompensated cirrhosis where the liver is extensively 
scarred and unable to do its function well (Franciscus, 2015), which leads to a 
measurable accumulation of intra-abdominal fluid due to the increase in portal 
venous pressure (El Saadany et al., 2005), however, this ascites cannot be 
treated with dietary sodium restriction and oral diuretic (Arroyo et al., 1996). 
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 Variceal Hemorrhage: This group includes the people in this age group who 
have viremia and decompensated cirrhosis induced portal hypertension 
(El Saadany et al., 2005) 
 Hepatic Encephalopathy: This group includes the people in this age group who 
have viremia and decompensated cirrhosis that characterized by changes in 
personality, intellectual impairment, and alteration in level of consciousness 
(‘Hepatic Encephalopathy’, 2015) 
 Hepatocellular Carcinoma: This group includes the people in this age group 
who have viremia and cirrhosis with a primary malignancy of the liver cells 
(‘Hepatocellular Carcinoma’, 2015) 
  Liver Transplant 1st Year: This group includes the people in this age group 
who have had conducted liver transplantation operation during this year. 
 Liver Transplant Subsequent Year: This group includes the people in this age 
group who have had conducted liver transplantation operation in the previous 
year or years 
 Cured: This group includes the people in this age group who cured from HCV 
either spontaneously or by HCV treatment and they do not have cirrhosis 
 Cured with Cirrhosis: This group includes the people in this age group who 
cured from HCV when they got HCV treatment, however, they do developed 
cirrhosis 
 Liver Related Deaths: This group includes the people in this age group who 
died as a consequence to HCV disease 
 Death from Background Mortality: This group includes the people in this age 
group who died due to any other causes rather than HCV disease. 
 
The current and future burden of HCV with the different policies will be estimated 
in the form of epidemiological and economic burden. In epidemiological burden we 
will follow all viremia cases, cirrhosis, HCC, and liver related deaths over the coming 
15 years. On the other hand, we will estimate the economic burden in the form of 
direct expenses that includes cost of treatment, consulting physicians, hospital 
admissions, and laboratory investigations. In addition to direct heath care cost, the 
indirect cost will be calculated as well. This indirect cost will be identified by 
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calculating Disability Adjusted Life Years (DALYs) which includes years of life lost 
due to disability (YLD), and years of life lost due to premature death (YLL). 
This model will be designed and analyzed by using “TreeAge Pro 2015” 
software application https://www.treeage.com/  
 
B. Different scenarios 
After establishing this model we will compare between three scenarios for control 
of HCV in Egypt where: 
 The first scenario: is a mimic for the current situation using the same treatment 
rate, cost of current treatment regimen for 125,000 cases, efficacy of the used 
drugs, current incidence rate, and estimate the burden of HCV in the present 
and in future if this scenario continue as it is. In this scenario, we used the 
triple and dual therapy for treating HCV cases in 2015 and  use the recent 
treatment protocol published in December 2015 by NCCVH that depend on 
SOF and DCV for treating cases starting from 2016 (Saeed, 2015).  
 The second scenario: will  study the effect of  increasing the treatment rate to 
treat 500,000 cases per year starting from 2016 with using the recent treatment 
protocol published in December 2015 by NCCVH that depend on SOF and 
DCV±RBV for treating cases starting from 2016 (Saeed, 2015).  
 The third scenario: will discuss the effect of ambitious strategy to treat about 1 
million cases in the upcoming five years and decrease the incidence rate by 
50% between2016-2020, then decrease the incidence rate to become 10% of 
the current rate. We also will use the recent treatment protocol published in 
December 2015 by NCCVH that depend on SOF and DCV±RBV for treating 
cases starting from 2016 (Saeed, 2015).  
 
C. Model Input: 
1. Population: 
The data of the population was based on data collected from “Egypt Statistical 
Year Book,2015” produced by Egyptian Central Agency for Public Mobilization and 
Statistics (CAPMAS).The population was divided into age groups with 5 year 
intervals (CAPMAS, 2015). We gathered people who were 60 years or older in one 
group. Table IV-1 presents the population data used in the model. 
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2. Prevalence 
The data of HCV prevalence was based upon results of the EHIS 2015. The 
EHIS 2015 had a nationally representative sample of Egypt. Among 842 primary 
sampling units (PSUs) (shiakhas/villages) from 25 governorates 624 PSUs were 
selected. Then household list in the sample were prepared and approximately 28,500 
individuals between 6 months and 59 years were identified for interviews and testing 
for HCV (Ministry of Health and Population [Egypt], El-Zanaty and Associates 
[Egypt], & ICF International, 2015). Two different types of laboratory tests were 
conducted, HCV antibody and HCV RNA.  We used the results of HCV RNA as it 
represents the chronic active hepatitis cases. Results were presented in five-year age 
groups for individuals from 1- 59 year (Table IV-1). The prevalence of HCV RNA for 
individual aged 1- 59 was 4.4%. The prevalence for people aged sixty years and 
above was assumed to be as equal as those in the age group 55-59 years.  
Table ‎IV-1 Distribution of Egyptian population and HCV RNA positive cases by 
age, 2015 
Age Group 
Population 
number * 
Probability of 
Healthy Population  
Probability of HCV 
RNA (+ve) cases  ** 
0- 04 9830000 0.9980 0.0020 
05-09 9126000 0.9995 0.0005 
10-14 8184000 0.9970 0.0030 
15-19 8389000 0.9920 0.0080 
20-24 8929000 0.9780 0.0220 
25-29 8399000 0.9700 0.0300 
30-34 6731000 0.9510 0.0490 
35-39 5281000 0.9400 0.0600 
40-44 4740000 0.9100 0.0900 
45-49 4350000 0.8870 0.1130 
50-54 3777000 0.8010 0.1990 
55-59 3084000 0.7790 0.2210 
>=60 5,993,000 0.7790 0.2210 
*Data from Egypt statistical yearbook, 2015 (CAPMAS, 2015). ** Data from Egyptian Health 
Issues Survey, 2015 (Ministry of Health and Population [Egypt], El-Zanaty and Associates 
[Egypt], & ICF International, 2015) 
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3. Incidence 
We used the most recent estimate for the incidence of HCV in Egypt of 
Breban et al. 2013, where a nationally represented data were used to give a realistic 
incidence for HCV. This model estimated the incidence of HCV nationwide around 
2.0/1000 PY which means that there are150,000 new HCV infections annually 
(Breban et al., 2013). 
4. Baseline health states 
2.1 Liver Fibrosis (F0, F1, F2, F3) 
The data of the baseline or initial probabilities of different stages of liver 
disease in each age group was based on data from Wong et al. 2000 paper for 
estimating the burden of HCV in United States (Wong et al., 2000). As we used 
Metavir classification for the grade of live fibrosis in our model, we divided the 
allocated probability of the baseline value of mild hepatitis in Wong paper equally 
between F0 and F1; while the allocated value for moderate hepatitis was equally 
divided between F2 and F3 (table IV-2). These baseline probabilities were calculated 
after taking into consideration the baseline probabilities of HCV related deaths and 
HCC. 
Table ‎IV-2 Baseline probabilities of different fibrosis stages by age 
Age Group F0 F1 F2 F3 
0- 04 0.00100 0.00100 0.00000 0.00000 
05-09 0.00025 0.00025 0.00000 0.00000 
10-14 0.00149 0.00149 0.00001 0.00001 
15-19 0.00396 0.00396 0.00004 0.00004 
20-24 0.00979 0.00979 0.001210 0.001210 
25-29 0.01335 0.01335 0.001640 0.001649 
30-34 0.01737 0.01737 0.00538 0.00538 
35-39 0.02125 0.02125 0.00659 0.00659 
40-44 0.02236 0.02236 0.01431 0.01431 
45-49 0.02790 0.02790 0.01786 0.01786 
50-54 0.02855 0.02855 0.04234 0.04234 
55-59 0.03144 0.03144 0.04662 0.04662 
>=60 0.00254 0.00254 0.05204 0.05204 
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2.2 Liver Cirrhosis (Compensated and Decompensated): 
Regarding the baseline probability of liver cirrhosis, we based also on the 
value of Wong et al. 2000 paper after dividing it between compensated liver cirrhosis 
and decompensated states of liver cirrhosis such as, ascites, variceal hemorrhage, and 
hepatic encephalopathy based on data from Asrani et al. 2014 research. In Asrani et 
al. 2014, a study conducted in Mayo Clinic for patients with advanced fibrosis 
undergoing magnetic resonance elastography between 2007–2011. During this period, 
430 patients were diagnosed as having advanced fibrosis and/or diagnosed clinically 
to have cirrhosis (Asrani et al., 2014). The baseline analysis for this cohort showed 
that 68% are compensated cirrhotic patient while 32% have evidence of 
decompensated cirrhosis including ascites, variceal hemorrhage, or hepatic 
encephalopathy (Asrani et al., 2014). Among people who met the criteria of 
decompensated cirrhosis, 60.44% suffered from ascites, 20.33% of decompensated 
cirrhotic patient had variceal hemorrhage, and 19.23% had hepatic encephalopathy 
(Asrani et al., 2014). Hence, the predicted prevalence of cirrhosis in (Wong, 2000) 
according to age group were divided as follow, 68% of this value allocated for initial 
probability for compensated cirrhosis state, 19.34% of it for initial probability for 
ascites  patients, 6.51% allocated for variceal hemorrhage state, and 6.15% for the 
baseline probability for hepatic encephalopathy state (Table IV-3 ).. 
Table ‎IV-3 Baseline probabilities of compensated cirrhosis and different 
decompensated cirrhosis states by age 
Age Group 
Compensate
d Cirrhosis 
Variceal 
Hemorrhage 
Diuretic 
Sensitivity 
Ascites 
Diuretic 
Refractory 
Ascites 
Hepatic 
Encephalopa
thy 
0-04 0.00000 0.00000 0.000000 0.000000 0.00000 
05-09 0.00000 0.00000 0.000000 0.000000 0.00000 
10-14 0.00000 0.00000 0.000000 0.000000 0.00000 
15-19 0.00000 0.00000 0.000000 0.000000 0.00000 
20-24 0.00000 0.00000 0.000000 0.000000 0.00000 
25-29 0.00000 0.00000 0.000000 0.000000 0.00000 
30-34 0.00233 0.00022 0.000331 0.000331 0.00021 
35-39 0.00285 0.00027 0.000405 0.000405 0.00026 
40-44 0.01095 0.00105 0.001557 0.001557 0.00099 
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45-49 0.01366 0.00131 0.001943 0.001943 0.00124 
50-54 0.03750 0.00359 0.005332 0.005332 0.00339 
55-59 0.04129 0.00395 0.005871 0.005871 0.00373 
>=60 0.07322 0.00701 0.010413 0.010413 0.00662 
 
2.3 HCC:  
In 2015, the number of hepatocellular carcinoma (HCC) due to HCV was 
estimated at 17,000 cases (Waked et al., 2014). Based on a retrospective study that 
reviewed the data of HCC patients who attended the outpatient clinic of HCC Unit, 
Ain Shams University Hospitals, Cairo, Egypt between January 2009 and December 
2011 (Shaker et al., 2013), and the distribution of HCC patients among the different 
age groups, the baseline probability of HCC among each age groups was calculated to 
keep the ratio between age groups as it was in the Ain Shams Study (Table IV-4). 
Table ‎IV-4 Baseline probabilities of HCC and Liver related deaths by age 
Age Group HCC Liver Related Death 
0-04 0.00000 0.00000 
05-09 0.00000 0.00000 
10-14 0.00000 0.00000 
15-19 0.00000 0.00000 
20-24 0.00001 0.00000 
25-29 0.00001 0.00000 
30-34 0.00003 0.00003 
35-39 0.00003 0.00010 
40-44 0.00044 0.00011 
45-49 0.00048 0.00090 
50-54 0.00103 0.00104 
55-59 0.00126 0.00290 
>=60 0.00078 0.00283 
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5. Disease progression probabilities 
Disease progression probabilities were based on back-calculated progression 
rates conducted by Razavi et al. 2013 for data US and UK data. The fibrosis 
progression rate between F0 to F1, F1 to F2, F2 to F3, F3 to cirrhosis, F3 to HCC, and 
cirrhosis to HCC were based on data collected from the US Surveillance, 
Epidemiology and End Results program between 1999-2009. As the collected data in 
Razavi et al. 2013 for fibrosis were classified by gender, we calculated the average 
progression probabilities between male and female. Also, we reduced the progression 
probability rate from F1 to F2 by 20% due to lower alcohol consumption in Egypt 
incomparable to US and UK which considered one of the factors that accelerates the 
progression rate.  In addition, the probabilities for the age group 60 years and above 
were calculated as an average for the probabilities of all age groups from 60 years to 
more than 85 years mentioned in the same paper (Table IV-5). Other probabilities of 
spontaneous clearance, progression from diuretic sensitivity ascites to diuretic 
refractory ascites, different decompensated cirrhotic states to liver related deaths, 
HCC to death, and from liver transplant to death were collected from literature (Table 
IV-6). 
Table ‎IV-5 HCV Annual disease Progression probability by age 
Age Group 
From F0 to 
F1 
From F1 to 
F2 
From F2 to 
F3 
From F3 to 
Cirrhosis 
From F3 to 
HCC 
From 
Cirrhosis 
to HCC 
0-04 0.0485 0.0280 0.0495 0.0000 0.0000 0.0030 
05-09 0.0485 0.0280 0.0495 0.0000 0.0000 0.0030 
10_14 0.0590 0.0344 0.0605 0.0070 0.0000 0.0030 
15-19 0.0590 0.0344 0.0595 0.0070 0.0000 0.0030 
20-24 0.0475 0.0276 0.0485 0.0230 0.0000 0.0030 
25-29 0.0475 0.0276 0.0485 0.0230 0.0000 0.0030 
30-34 0.0345 0.0200 0.0430 0.0520 0.0000 0.0045 
35-39 0.0345 0.0200 0.0430 0.0520 0.0000 0.0045 
40-44 0.1275 0.0740 0.1310 0.0810 0.0005 0.0080 
45-49 0.1275 0.0740 0.1310 0.0810 0.0005 0.0080 
50-54 0.1570 0.0912 0.1605 0.0440 0.0010 0.0130 
55-59 0.1570 0.0912 0.1605 0.0440 0.0010 0.0130 
>=60 0.1840 0.1334 0.1886 0.1414 0.0021 0.0304 
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Table ‎IV-6 HCV Annual disease Progression probability 
From To Progression 
probability 
Source 
Acute HCV Spontaneous Cure 0.175 (El-Attar et 
al., 2010) 
Incident case Fulminant 0.005 (El Saadany 
et al., 2005) 
Cirrhosis Diuretic Sensitive Ascites 0.025 (El Saadany 
et al., 2005) 
Cirrhosis Hepatic encephalopathy 0.004 (El Saadany 
et al., 2005) 
Cirrhosis Liver transplant 0.0015 (Shelbaya et 
al., 2015) 
Cirrhosis Variceal Hemorrhage 0.0011 (El Saadany 
et al., 2005) 
Diuretic Sensitive Ascites Diuretic Refractory 
Ascites 
0.067 
(Razavi et 
al., 2014) 
Diuretic Sensitive Ascites Liver related death 0.11 
Diuretic Refractory 
Ascites 
Liver related death 0.33 
Variceal Hemorrhage Liver related death, year 1 0.4 
Variceal Hemorrhage Liver related death, 
subsequent years 
0.13 
Hepatic encephalopathy Liver related death, year 1 0.68 
Hepatic encephalopathy Liver related death, 
subsequent years 
0.4 
Hepatocellular carcinoma Liver related death, year 1 0.707 
Hepatocellular carcinoma Liver related death, 
subsequent years 
0.162 
Liver Transplant Liver related death, year 1 0.21 
(Wong et al., 
2000) Liver Transplant Liver related death, 
subsequent years 
0.057 
Decompensated Cirrhosis Liver Transplant 0.031 (El Saadany 
et al., 2005) 
 
6.  Liver related Deaths 
It was estimated that the liver related deaths in 2015 was around 35,000 cases. 
For estimating the annual rate of liver related deaths by age group, we used the annual 
rate of liver related deaths collected by US 2013 surveillance of viral hepatitis 
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(Division of Viral Hepatitis, CDC, 2015); then this rate was adjusted to reach the 
35,000 liver related deaths in Egypt keeping the ratio between age groups as it is in 
US 2013 data of surveillance of viral hepatitis. Table IV-1 show the probability of 
liver related deaths by age group used in our model. 
7. Probability of death from background  
This model take into consideration the probability of death from other causes. As this 
probability is different according to different age groups. We have extracted the 
mortality rate of each age group of Egypt from Global Health Observatory (GHO) 
data repository of WHO (GHO-WHO, 2013). Then, probability of background 
mortality was calculated for each age group through using the following equation:  
Probability= 1- exp
(-rt) 
where r express for rate and t express for time. The probability of background 
mortality, used in this model, are shown in Table IV-10. 
8. Direct costs 
The data for the direct cost of medical expenses including HCV drugs and 
other medical care expenses according to different stages of liver disease were 
collected from different literatures between 2014 and 2015 that based on Egyptian 
context. The prices of HCV drugs were based on the prices of these drugs for the 
government (Table IV-7). Regarding to the cost of the IFN- based regimen (SOF 
+PEG-IFN/RBV) for 12 weeks, it was 9600 LE which is equal $ 1,226 (Esmat, n.d.), 
while the cost of IFN- free regimen (DualTherapy) for 24 wks.was 12,600 LE which 
is equal $1,609 (Esmat, n.d.); therefore the average of the cost of this regiment which 
was used in 2014 for treatment HCV patients was $ 1417.5. 
As the economic burden will be estimated over a long period of time cost 
adjustment will be applied through applying 3% discounting rate. 
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Table ‎IV-7 Annual Cost of different states of HCV in US $ 
Variable First Year after 
Diagnosis $ 
Following Year 
$ 
Data Source 
Cost of medical Care of 
F0, F1, F2, or F3 * 
838 424 
(Obach et al., 2014) 
Cost of medical Care of 
Cirrhosis * 
654 602 
Cost of medical Care of 
Decompensated Cirrhosis 
(Ascites, Variceal 
Hemorrhage, or Hepatic 
Encephalopathy )* 
1184 1179 
Cost of medical Care of 
Hepatocellular 
Carcinoma 
2158 2088 
Cost of liver transplant  * 42500 3500 (Estes et al., 2015) 
Triple Therapy (SOF + 
PEG-INF/RBV) 
1226 ----- (Esmat, n.d.) 
Dual Therapy (SOF + 
RBV) 
1609 ----- (Esmat, n.d.) 
Average cost of Triple 
and Dual therapy 
1417.5   
SOF + DCV 319.3 ---- (Abdelsalam, 2015) 
* This medical care expenses did not include any of treatment regimen for HCV. 
Also, it did not include HCV genotyping cost as it was not included as one of the 
required investigations in the protocol of HCV management in Egypt. 
9. Indirect Burden (DALYs) 
The indirect cost were estimated based on calculating disability adjusted life 
years (DALYs). DALYs is a metric for measuring the burden of diseases which 
introduced for the first time in the Global Burden of Disease study measured the 
burden for about 100 diseases in 1990 (Murray & Lopez, 1996). DALYs include 
years of life lost to disability (YLDs) and years of life lost due to premature death 
(YLLs). Disability weights for calculating YLDs were calculated based on data in 
Table IV-8.  
Table ‎IV-8  Disability weight of different health states of liver disease(YLDs) 
Health State Disability weight 
Undiagnosed Chronic Hepatitis cases 0 
Diagnosed Symptomatic Chronic Hepatitis 
cases 
If <30 Y zero, others 0.1 
weighted average for Diagnosed 
symptomatic Chronic Hepatitis cases 
If <30 Y zero, others 0.015 
Compensated Cirrhosis If <30 Y zero, others 0.3 
Esophageal Varices 0.4 
Hepatic Encephalopathy 0.8 
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Ascites 0.4 
HCC 0.6 
(Estes et al., 2015) 
YLLs will be identified by using WHO life expectancy table of Egypt which 
show number of years expected to be lived by each age group. The life expectancy in 
Egypt has increased in the last 20 years. Life expectancy for male has increased from 
63.0 years (IHME, n.d.) in 1990 to 68.3 years (GHO-WHO, 2013) in 2013 while the 
female life expectancy has increased from 67.7 years (IHME, n.d.) to 73.6 years 
(GHO-WHO, 2013) in the same period. (IHME, n.d.). The life expectancy for 
Egyptian population by age group was collected from Global Health Observatory data 
repository of WHO then the average of life expectancy of male and female at the 
same age group was calculated (Table IV-9). 
 
Table IV-10 Probability of Death from 
Background Mortality, Egypt 2013 
Age Group Probability of Death 
1-4 years 0.000758 
5-9 years 0.000478 
10-14 years 0.000392 
15-19  years 0.000563 
20-24 years 0.000835 
25-29 years 0.001029 
30-34 years 0.001343 
35-39 years 0.001597 
40-44 years 0.002358 
45-49 years 0.004887 
50-54 years 0.008921 
55-59 years 0.012259 
60-64 years 0.019302 
65-69 years 0.030268 
70-74 years 0.049122 
75-79 years 0.07991 
80-84 years 0.121357 
85-89 years 0.179102 
90-94 years 0.244894 
95-99 years 0.312166 
100+ years 0.378889 
 
Table IV-9 Life expectancy,  
Egypt 2013 
Age Group Life expectancy 
1-4 years 71.65 
5-9 years 67.85 
10-14 years 63 
15-19  years 58.1 
20-24 years 53.25 
25-29 years 48.5 
30-34 years 43.7 
35-39 years 39 
40-44 years 34.25 
45-49 years 29.65 
50-54 years 25.25 
55-59 years 21.3 
60-64 years 17.45 
65-69 years 13.95 
70-74 years 10.8 
75-79 years 8.2 
80-84 years 6.1 
85-89 years 4.45 
90-94 years 3.35 
95-99 years 2.65 
100+ years 2.1 
(GHO-WHO, 2013) 
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The monetary value of one DALY was assigned to be $6265 (Estes et al., 
2015). This value was based on calculating the mean value of lost productivity, lost 
earning, and the value of a statistical life year (VSLY) by Estes et al., 2015. Also, it 
was assumed that there will be 3% annual increase in the value of the DALY between 
2015 and 2025. 
10. SVR for different treatment regimen 
On one hand, SVR 12 for triple therapy (SOF + PEG-INF/RBV) was 
estimated to be 90%  for 12 weeks treatment course (Doss et al., 2015), while it was 
83.3% for the dual therapy (SOF +RBV) for 24 weeks treatment course (Wehmeyer et 
al., 2015). We calculated the average of both regimen (86.65%) and use it in our 
model to express about the efficacy of HCV treatment protocols in 2015. 
On the other hand, SVR 12 for the recent treatment protocol declared by 
NCCVH which contains SOF and DCV± RBV was applied in our model from 2016 
till 2025. Due to limited literature and small sample size in studies estimating the 
efficacy of this protocol on G4, we calculated the average of SVR 12 of this protocol 
on available literature for different genotypes which was 95.4% (Asselah, 2014 ; 
Degasperi & Aghemo, 2014 ; Nelson et al., 2015 ; Wyles et al., 2015). This calculated 
average was almost similar to the one declared by the head of NCCVH about the 
efficacy of this new combination which was 95% (Alneweihy, 2015). 
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V. Results 
A. Epidemiological Burden of HCV 
1. Scenario I: 
Under Scenario I, we studied the impact adopting this scenario on the 
epidemiological burden of HCV. This scenario represent the current  situation where 
we used the same treatment rate (about 125,000 patients treated annually), the same 
treatment regimen applied by NCCVH in 2015 which composed of the triple and dual 
therapy for treating HCV cases (NCCVH, 2015), then the recent treatment protocol 
published in December 2015 by NCCVH that depend on SOF and DCV for treating 
cases starting from 2016 (Saeed, 2015), the current cost of these treatment regimens, 
efficacy of the used drugs, and the current incidence rate. The model calculated the all 
HCV viremia cases annually, number of cases under different stages of liver fibrosis 
(F0-F3), annual number of liver cirrhosis cases either compensated or decompensated, 
hepatocellular carcinoma, and liver related deaths.  
The results showed that all HCV viremia cases slightly decreased from 4,664,037 
cases by end of 2015 to 4,105,505 cases by 2025 which represent 12% decrease from 
the viremia in 2015. The number of compensated cirrhosis cases will increase 
gradually to peak in 2019, at 3.8% above the 1,018,515 compensated cirrhosis cases 
at 2015, then decline to reach 991,282 cases by 2025 which means 2.7% less than 
2015. On the other hand, the decompensated cirrhosis cases decreased by 69.5% from  
110,840 patients in 2015 to  33,839 by 2025 (Figure V1). 
 Figure V -1  Number of chronic HCV patients by different disease stages, 2015-2025 
41 
 
The overall number of cases with cirrhosis (compensated and decompensated) showed 
9% decrease in comparison to the number of cases in 2015 to reach 1,025,122 cases 
by 2025. 
The number of HCC showed gradual increase over the time to reach the peak 
26,682 cases by 2023 then slightly decreased to reach 25,544 cases which is 42.3% 
higher than the situation at 2015 of 17,953 cases (Figure V3). During this 10 years 
period the liver related death was expected to decline by 43.6% according to the 
model to reach 25,907 cases by 2025 (Figure V2). 
  
 
 
 
 
 
 
 
 
 
 
2. Scenario II: 
During this scenario we estimated the effect of  increasing the treatment rate to 
treat  about 500,000 cases per year starting from 2016 with using the recent treatment 
protocol published in December 2015 by NCCVH that depend on SOF and DCV± 
RBV (Saeed, 2015). 
The results revealed that the total HCV viremia cases will decline by 56.5% from 
4,664,037 cases by end of 2015 to 2,027,717 cases by 2025 (Figure V4). The number 
of compensated cirrhosis cases will also decreases from 1,018,515 compensated 
cirrhosis cases at 2015 to 451,262 cases by 2025 which means 55.7% less than the 
cases in 2015, while the decompensated cirrhosis cases decreased by 84.9% from 
110,840 patients at 2015 to 16,756 cases by 2025 (Figure V5); and the overall number 
Figure V -2  Impact of current 
management scenario on the number of 
HCC over time 
 
Figure V -3  Impact of current 
management scenario on Liver Related 
deaths over time 
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of cases with cirrhosis (compensated and decompensated) showed 58.6% decline 
between 2015 and 2025 to reach 468,018 cases by 2025. 
 
Figure ‎V -4  Impact of adopting different management scenarios on total number 
of HCV viremia cases, 2015-2025 
 
 
 
 
In addition, the number of HCC showed  gradual increase over the time by 19.3% 
to reach the peak 21,424 cases by 2018, then slightly decreased to become 35.1% 
Figure V -5  Impact of adopting Scenario II on number of cirrhosis 
(compensated and decompensated) cases, 2015-2025 
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below the  2015 base of  17,953 cases to reach 11,650 cases by 2025 (Figure V7). 
Also, the liver related death was expected to decline by 69.1%  from 45.898  deaths to 
reach 14,195 cases by 2025 (Figure V6). 
 
 
3. Scenario III: 
During this scenario we estimated will discuss the effect of treatment about 1 
million cases in  the coming four years and decrease the incidence rate by 50% 
between 2016-2020, then decrease the incidence rate to become 10% of the current 
rate. We used the recent treatment protocol published in December 2015 by NCCVH 
that depend on SOF and DCV±RBV for treating cases starting from 2016 (Saeed, 
2015). 
The results revealed dramatic decline in all epidemiological burden indicators 
where  the total HCV viremia cases showed great decline by 86.3% from 4,664,037 
cases by end of 2015 to 636,652 cases by 2025 (Figure V4).The number of 
compensated cirrhosis cases will also decreases from 1,018,515 compensated 
cirrhosis cases at 2015 to 198,817 cases by 2025 which means 80.5% lower than the 
cases in 2015, while the decompensated cirrhosis cases decreased by 92.5% from  
110,840 patients at 2015 to  8,314 cases by 2025 (Figure V8); and the overall number 
Figure V -7  Impact of adopting scenario II 
on the number of HCC  
 
Figure V -6  Impact of adopting scenario II 
on the number of liver related deaths 
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of cases with cirrhosis (compensated and decompensated) showed 81.7% decline 
between 2015 and 2025 to reach 207,130 cases by 2025. 
 
 
In addition, The implementation of scenario III  caused 70.6%  decline in HCC 
cases from  17,953 cases to reach 5,273 cases by 2025 (Figure V10). Also, the liver 
related death was showed more decline where it became 86.6%  less during this 10 
years period from 45.898  deaths to reach 6,139 cases by 2025 (Figure V9).  
Figure V -8  Impact of adopting Scenario III on number of cirrhosis (compensated and 
decompensated) cases, 2015-2025 
Figure V -10  Impact of adopting scenario 
III on the number of HCC 
 
Figure V -9 Impact of adopting scenario 
III on the number of liver related deaths 
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4. Comparison between the three Scenarios: 
By comparing the impact of the three scenarios on the epidemiological burden of 
HCV in Egypt between 2015 and 2025, we found that: 
 Adoption of Scenario II will drop the total HCV viremia cases by 50.6% fewer 
than Scenario I by 2025, while the adoption of Scenario III will go beyond this 
level to reach 84.5% lower than Scenario I , where it reaches only 636,652 cases 
instead of 4,105,505 patients in Scenario I (Figure V11) 
 Implementing Scenario II will result in having 468,018 cirrhosis cases by 2025 
incomparable to 1,025,122 cases in Scenario I, a 54.3% decline lower than 
Scenario I, while it becomes more lower with Scenario III ,a 79.8% reduction 
compared with Scenario I by 2025 (Figure 11) 
 
 
 
 The number of HCC in Scenario II will decrease by 54.4% as compared to 
Scenario I to 11,650 cases, and decrease more with adopting Scenario III to 
reach 5,273 as compared to 25,544 in Scenario I (Figure V12) 
 Also liver related deaths will decrease in Scenario II 45.2% lower than 
Scenario I  to 12,726 deaths, and decline by 76.3% from Scenario I after 
implementing Scenario III to become only 6,139 (Figure V12) 
 
Figure V -11  Impact of adopting different management scenarios on 
total viremia and cirrhosis by 2025 
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Figure V -12  Impact of adopting different management scenarios on 
HCC and liver related deaths by 2025 
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B. Economic Burden 
1. Scenario I: 
It was estimated by the model that the direct costs of management HCV under  
Scenario 1 (the current  management scenario) would be  $2,597,875,687 at 2015 and 
decreased gradually to reach $ 1,753,385,280 by 2025 which means that the direct 
costs decreased by 32.5% between 2015-2025 (Figure V13). The cumulative direct 
cost between 2015-2025 were estimated $23,178,072,617. The DALYs decreased by 
78.9%, from 806,756 in 2015 to 170,038 by 2025 (Figure V14), and the cumulative 
DALYs were 3,794,828. Based on these DALYs, the indirect cost also decreased 
gradually from 5,344,758,798 to 1,126,502,104 by 2025 (Figure V15). The 
cumulative indirect cost were calculated $25,140,734,281 from 2015 to 2025. And the 
total costs associated with chronic active HCV infection in 2025 ($2,879,887,384) 
were 63.7% less than that in 2015 ($7,942,634,484) (Figure V16), where the 
cumulative total costs were estimated at $48,318,806,898. 
2. Scenario II: 
Under Scenario II, the estimated direct costs of management HCV was decreased 
53.2% from 2015 value to $ 1,216,061,709 at 2025 (Figure V13). The cumulative 
direct cost were estimated $20,478,601,172 between2015-2025. The DALYs 
decreased from 806,756 in 2015 to 93,410 by 2025, an 88.4% decline (Figure V14). 
Based on these DALYs, the indirect cost also decreased by 2025 to 1,126,502,104 $ 
618,842,604 (Figure V15). The cumulative DALYs were estimated 3,356,612, and the 
cumulative indirect cost were calculated $22,237,554,464 between 2015 and 2025. 
And the total costs associated with chronic active HCV infection decreased 76.9% 
from2015 value to reach $ 899,324,519 by 2025 (Figure V16). The cumulative total 
costs were estimated $42,716,155,636. 
3. Scenario III: 
Based on Scenario III, the estimated direct costs of management HCV showed 
minimal increase in 2016 by 0.2% to reach $2,602,320,222, then it decreased by 
53.2% from 2015 value to $ 1,216,061,709 at 2025 (Figure V13). The cumulative 
direct cost between 2015-2025 were estimated at $16,202,234,991. The DALYs 
decreased from 806,756 in 2015 to 93,410 by 2025, an 88.4% decline (Figure V14), 
and the cumulative DALYs were 2,718,098. Based on the DALYs, the indirect cost 
also decreased by 2025 to 1,126,502,104 $ 618,842,604 (Figure V15). The cumulative 
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indirect cost from 2015 to 2025 were calculated $18,007,401,689. And the total costs 
associated with chronic active HCV infection decreased 76.9% from2015 value to 
reach $ 899,324,519 by 2025 (Figure V16). The cumulative total costs were estimated 
$ 34,209,636,680. 
Figure ‎V -13  Impact of the different management scenario on the direct cost of 
HCV management - Egypt, 2015-2025 
 
 
Figure ‎V -14  Impact of the different management scenario on Disability adjusted 
life years due to HCV- Egypt, 2015-2025 
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Figure ‎V -15  Impact of the different management scenario on the indirect cost of 
HCV - Egypt, 2015-2025 
 
 
Figure ‎V -16  Impact of the different management scenario on the total cost of 
HCV management- Egypt, 2015-2025 
 
4. Comparison between the three Scenarios: 
By comparing the economic burden of HCV when adopting the Scenario II 
and Scenario III as compared to the current scenario (Scenario I) in Egypt between 
2015 and 2025, we found that: 
 Adoption of Scenario II will decrease the cumulative DALYs by 11.5%, from 
3,794,828 in Scenario I to reach 3,356,612 (Figure V17), which will save 
$2,903,179,817 as indirect costs. Also, the cumulative direct costs will 
decrease by11.6% s compared with Scenario I to reach $20,478,601,172 
50 
 
(Figure V18). Hence, the cumulative total cost will decrease as well and save 
$5,602,651,262 (Figure V18) 
 Adoption of Scenario III will decrease the cumulative DALYs by 28.4% from 
Scenario I value to become 2,718,098 (Figure V17), which will save 
$7,133,332,592 as indirect costs. Also, the cumulative direct costs will 
decrease by 30.1% as compared with Scenario I to reach $16,202,234,991 
(Figure V18). Hence, the cumulative total cost will decrease as well by 29.2% 
and save $14,109,170,218 (Figure V18) 
Figure ‎V -17  The cumulative Disability Adjusted Life Years of the three 
management Scenario of HCV, Egypt 2015-2025 
 
 
Figure ‎V -18  The cumulative direct, indirect and total cost of the three 
management  scenario of HCV, Egypt 2015-2025 
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C. Cost Effectiveness 
Cost effectiveness analysis was conducted to identify the most cost effective 
scenario. The analysis showed that both of Scenario I and Scenario II were absolute 
dominated by Scenario III as both of them have higher cost and higher DALYs (low 
effectiveness) than Scenario III. Therefore, Scenario III is the most cost effective 
scenario. 
Adoption of Scenario III instead of Scenario I between 2015 and 2025 will avert 
1,076,729 DALYs, and save $6.97 billion as direct costs and $14.11 billion as total 
costs. Therefore, for direct costs, the ICER for Scenario III was -$6,497 for each 
DALY averted as compared to Scenario I. In addition, for total costs, the ICER for 
Scenario III was -$13,104 for each DALY averted as compared to Scenario I 
 Adoption of Scenario III instead of Scenario II between 2015 and 2025 will avert 
638,514 DALYs, and save $4.28 billion as direct costs and $8.51 billion as total costs. 
Therefore, for direct costs, the ICER for Scenario III was -$6,697 for each DALY 
averted as compared to Scenario II. In addition, for total costs, the ICER for Scenario 
III was -$13,322 for each DALY averted as compared to Scenario II. 
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VI. Discussion and Recommendations: 
 
With the rapid progress in HCV treatment drugs, not only in their efficacy but also 
in their prices, in addition to availability of recently published data about the 
prevalence of HCV in Egypt, this paper presents an updated figure for the current and 
the future burden of this disease from economic and epidemiological prospective. In 
addition, it has assessed three different scenarios for management of this huge public 
health problem facing our beloved country to enable the policy makers to choose the 
most cost effective strategy that is capable of reducing the economic and 
epidemiological burden of this disease at the country level. 
This paper revealed that the total economic burden of HCV in Egypt according to 
the current situation is $7.94 billion which is equivalent to 2.7% of Egypt GDP 
(‘Egypt Home’, 2015). The current direct healthcare costs of HCV in Egypt is about 
$2.6 billion which consume around 17.4% of the total health expenditure in Egypt 
(‘WHO | Hepatitis C’, 2015).  
Under the current management strategy, Scenario I, small reduction in the 
prevalence of HCV is expected to be achieved after 10 years where it is estimated that 
we will have about 4.1 million chronic active HCV patients, 25% of them are in 
cirrhotic stage, around 25 thousands suffer from HCC, and expected to still have high 
annual number of deaths, about 25 thousands deaths at 2025. In addition, the 
economic burden of this strategy is very high where the direct costs are estimated at 
$23.3 billion, and the total costs are $48.3 billion between 2015-2025.  
Adoption of Scenario II which aims to increase the number of treated patients to 
reach half million annually showed significant decrease in all burdens of the disease, 
however, adoption of Scenario III which focus aims not only to increase the treatment 
rate to reach 1 million patient annually in the coming five years but also adopting 
prevention strategy to decrease the annual incidence by 90% in the coming 10 years 
will achieve dramatic decrease in the burden of disease. The chronic active HCV 
cases are estimated to be about 636 thousands cases with a prevalence rate around 
0.7%, and with only $16.2 billion as a direct costs, and total costs $34.2 billion 
between 2015-2025 which is 29.2% lower than the cost of Scenario I. Also, it is the 
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most cost effective strategy where its adoption will save $13,104 for each DALY 
averted as compared to the total costs of Scenario I. 
It is highly important for success of this strategy to adopt a comprehensive 
approach for dealing with this huge challenge, where the “Plan of Action for the 
Prevention, Care and Treatment of Viral Hepatitis, Egypt, 2014-2018” provides the 
base for this move. We need to focus on availability and accessibility of the new HCV 
treatment drugs to be able to absorb the huge number of patients required to be treated 
annually and decrease patients’ waiting list. Also, proper infection control measures, 
implementing national standards for blood transfusion and testing, increase public 
awareness regarding to mode of transmission and methods of protection are highly 
important issues in decreasing the incidence of the disease to ensure proper success of 
the strategy. The last thing, which is missing in the Egyptian national plan that needs 
a special focus to ensure the success of Scenario III is the screening pillar. It is highly 
important to adopt a mass screening policy as it is estimated that the newly diagnosed 
HCV patients annually are only 110,000 patients (Razavi et al., 2014). This mass 
screening policy is an important tool for success of scenario III to ensure early 
detection of patients to provide proper treatment for them and preventing them from 
spreading the infection. 
In brief, adoption of the current scenario for HCV management will have minimal 
effect on decreasing the epidemiological burden of the disease, and have a high direct 
and indirect cost. On the other hand, adoption of more rigorous strategy increasing the 
treatment rate, screening, and decrease the disease transmission as in Scenario III will 
allow dramatic response in the epidemiological burden of the disease and significantly 
save direct and indirect costs. 
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Annex 
 
The model structure for estimating the economic and epidemiological burden of HCV 
in Egypt, 2015-2025 
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